Press release: UPPSALA, Sweden, November 23, 2021 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now starting the delivery of Olink® Signature Q100, facilitating hands-on access for researchers to Olink technology with a new benchtop system dedicated to multiplex protein biomarker measurement.
Olink® Signature Q100 now offers a new solution designed for readout of Olink® Target and Olink® Focus protein biomarker panels, enabling researchers to run Olink kits more easily and conveniently in their own labs using as little as one microliter of plasma or serum to measure protein concentrations for up to 92 proteins simultaneously. This new instrument will allow more researchers to access high-quality proteomics data with Olink technology.
“The Signature instrument has been very well received since orders started earlier this year and we are pleased to see how our customers are showing interest in this new product. Beta tests have been performed at six customer’s labs, and the data obtained shows that Olink® Target and Focus products perform very well in this compact, benchtop format,“ says Jon Heimer, CEO of Olink Proteomics.
This is one of Olink’s many developments currently underway to provide a broader offering of application-focused mid-plex solutions and more flexible customer offerings. It demonstrates Olink’s commitment to innovate and improve across all aspects of our growing portfolio, to better serve the needs of our customers within protein biomarker research.
“The Signature instrument is a welcome addition to the Olink family. Its small footprint, ease of use, and user-friendly interface make it a great addition to any lab performing Olink analysis,” says Tara Bryce, Operations Manager, CRLB-GMEL Clinical Research Laboratory & Biobank – Genetic & Molecular Epidemiology Laboratory, Hamilton, Canada.
- Developed specifically for the high quality of Olink® Target 96/48 and Focus (custom designed) protein biomarker panels, as well as future custom biomarker solutions presently under development – currently covering over 1100 different thoroughly validated protein assays
- Low investment threshold, broadening access to protein biomarker analysis to more researchers than ever before
- User-focused design and intuitive interface, including integrated software and IFC loader
- Small, compact footprint
For more details, please visit www.olink.com/signature
For more information please contact:
Jan Medina, CFA, VP Investor Relations & Capital Markets, Olink
Mobile: +1 617 802 4157
Andrea Prander, Corporate Communications Manager, Olink
Mobile: + 46 768 775 275
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.